Clinical Trials Regulatory Approval Preclinical Studies Experimental Treatments Gender Differences FDA Approval Repurposing Drugs Ezogabine Phase 3 Trials Chimeric Peptides Mechanism of Action Targeted Therapy Phase Trials Antifungal Research FDA Regulations Cancer Therapies Anti-inflammatory Medications Monoclonal Antibodies Patient Trials Regulatory Agencies Antibody Therapy Accelerated Approval Nektar Therapeutics Personalized Medicine Therapeutic Applications
The once-daily medicine targets neurokinin signaling to offer an option for women who cannot use estrogen therapy.